UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000010910
Receipt number R000012748
Scientific Title A prospective cohort study of thrombosis and tissue factor in patients with pancreas or biliary tract cancer
Date of disclosure of the study information 2013/06/10
Last modified on 2020/12/14 22:41:51

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A prospective cohort study of thrombosis and tissue factor in patients with pancreas or biliary tract cancer

Acronym

Trombosis and tissue factor in pancreas or biliary tract cancer

Scientific Title

A prospective cohort study of thrombosis and tissue factor in patients with pancreas or biliary tract cancer

Scientific Title:Acronym

Trombosis and tissue factor in pancreas or biliary tract cancer

Region

Japan


Condition

Condition

Patients with pancreas or biliary tract cancer who have not thrombosis

Classification by specialty

Hepato-biliary-pancreatic medicine Hematology and clinical oncology Hepato-biliary-pancreatic surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Clarifying whether pancreas and biliary tract cancer produce tissue factor and release the microparticle of it(Part I), and whether the microparticle relates to the thromboembolism in those patients(Part II)

Basic objectives2

Bio-availability

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

The concentration of tissue factor in resected specimen(Part I). The relationship between the microparticle level of tissue factor in the serum and the incidence of thromboembolism(Part II)

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Part I; 1)clinically or pathologically diagnosed as pancreas or biliary tract cancer, 2)clinically diagnosed as resectable before the operation, 3)provided written informed consent, 4)without obstructive jaundice nor acute pancreatitis
Part II; 1)clinically or pathologically diagnosed as pancreas or biliary tract cancer, 2)clinically diagnosed as unresectable, 3)provided written informed consent, 4)without obstructive jaundice nor acute pancreatitis

Key exclusion criteria

Part I; 1)have the medical history of thromboembolism whithin 5 years or have thrombosis at the time of inclusion, 2)inappropriate to this this study judged by the investigator
Part II; 1)have the medical history of thromboembolism whithin 5 years or have thrombosis at the time of inclusion, 2)allergy to the contrast enhancing media, 3)intake regularly anti-coagulant agent, 4)with obstrucive janudice or acute pancreatitis, 5)inappropriate to this this study judged by the investigator

Target sample size

200


Research contact person

Name of lead principal investigator

1st name Shinichi
Middle name
Last name Ohkawa

Organization

Kanagawa Cancer Center

Division name

Division of Hepatobiliary and Pancreas Oncology

Zip code

2410815

Address

2-3-2, Nakao, Asahi-ku, Yokohama City, Kanagawa Pref.

TEL

045-520-2222

Email

s-ohk@kcch.jp


Public contact

Name of contact person

1st name Satoshi
Middle name
Last name Kobayashi

Organization

Kanagawa Cancer Center

Division name

Division of Hepatobiliary and Pancreas Oncology

Zip code

2410815

Address

2-3-2, Nakao, Asahi-ku, Yokohama City, Kanagawa Pref.

TEL

045-391-5761

Homepage URL


Email

kobayashis@kcch.jp


Sponsor or person

Institute

Kanagawa Cancer Center

Institute

Department

Personal name



Funding Source

Organization

Kanagawa Cancer Center

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kanagawa Cancer Center

Address

2-3-2, Nakao, Asahi-ku, Yokohama City

Tel

0455202222

Email

chiken-jimu@kcch.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

神奈川県立がんセンター(神奈川県)


Other administrative information

Date of disclosure of the study information

2013 Year 06 Month 10 Day


Related information

URL releasing protocol

Unpublished

Publication of results

Unpublished


Result

URL related to results and publications

http://www.mtoyou.jp/jocs-2/

Number of participants that the trial has enrolled

276

Results

Incidence of CAT was 6.6% in pancreatic cancer cohort.
Plasma Tissue factor (TF) level was significant higher in patients with pancreatic cancer than that of healthy volunteers, even if patients did not show CAT.
Positive and negative predictive value was 23.1% and 94.6% using 100 pg/mL of plasma TF level as a cut-off, which were better than d-dimer or khorana score.

Results date posted

2020 Year 12 Month 14 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results

2018 Year 11 Month 04 Day

Baseline Characteristics

Total of 197 and 79 patients with pancreatic cancer and biliary tract cancer

Participant flow

Patients and helthy volunteers were obtained written informed consent, and they were prospectively registerd to this study. Then, plasma sample was collected.

Adverse events

Not applicable

Outcome measures

Incidence of CAT
Plasma TF level

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2013 Year 05 Month 27 Day

Date of IRB

2013 Year 05 Month 27 Day

Anticipated trial start date

2013 Year 06 Month 10 Day

Last follow-up date

2018 Year 03 Month 31 Day

Date of closure to data entry

2018 Year 03 Month 31 Day

Date trial data considered complete


Date analysis concluded



Other

Other related information

Prospective cohort study


Management information

Registered date

2013 Year 06 Month 09 Day

Last modified on

2020 Year 12 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012748


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name